6.
Nodjikouambaye Z, Adawaye C, Mboumba Bouassa R, Sadjoli D, Belec L
. A systematic review of self-sampling for HPV testing in Africa. Int J Gynaecol Obstet. 2020; 149(2):123-129.
DOI: 10.1002/ijgo.13112.
View
7.
Munoz N, Bosch F, de Sanjose S, Herrero R, Castellsague X, Shah K
. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6):518-27.
DOI: 10.1056/NEJMoa021641.
View
8.
Benard E, Drolet M, Laprise J, Gingras G, Jit M, Boily M
. Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis. Lancet Public Health. 2023; 8(10):e788-e799.
PMC: 10557953.
DOI: 10.1016/S2468-2667(23)00180-9.
View
9.
Ghittoni R, Accardi R, Chiocca S, Tommasino M
. Role of human papillomaviruses in carcinogenesis. Ecancermedicalscience. 2015; 9:526.
PMC: 4431404.
DOI: 10.3332/ecancer.2015.526.
View
10.
Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F
. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer. 2013; 49(15):3262-73.
DOI: 10.1016/j.ejca.2013.04.024.
View
11.
Drolet M, Benard E, Perez N, Brisson M
. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019; 394(10197):497-509.
PMC: 7316527.
DOI: 10.1016/S0140-6736(19)30298-3.
View
12.
Munoz N, Manalastas Jr R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K
. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009; 373(9679):1949-57.
DOI: 10.1016/S0140-6736(09)60691-7.
View
13.
Williamson A
. Recent Developments in Human Papillomavirus (HPV) Vaccinology. Viruses. 2023; 15(7).
PMC: 10384715.
DOI: 10.3390/v15071440.
View
14.
Scheurer M, Tortolero-Luna G, Adler-Storthz K
. Human papillomavirus infection: biology, epidemiology, and prevention. Int J Gynecol Cancer. 2005; 15(5):727-46.
DOI: 10.1111/j.1525-1438.2005.00246.x.
View
15.
Poole D, Tracy J, Levitz L, Rochas M, Sangare K, Yekta S
. A cross-sectional study to assess HPV knowledge and HPV vaccine acceptability in Mali. PLoS One. 2013; 8(2):e56402.
PMC: 3576405.
DOI: 10.1371/journal.pone.0056402.
View
16.
De Groot A, Tounkara K, Rochas M, Beseme S, Yekta S, Diallo F
. Knowledge, attitudes, practices and willingness to vaccinate in preparation for the introduction of HPV vaccines in Bamako, Mali. PLoS One. 2017; 12(2):e0171631.
PMC: 5305061.
DOI: 10.1371/journal.pone.0171631.
View
17.
Louie K, de Sanjose S, Mayaud P
. Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review. Trop Med Int Health. 2009; 14(10):1287-302.
DOI: 10.1111/j.1365-3156.2009.02372.x.
View
18.
de Sanjose S, Quint W, Alemany L, Geraets D, Klaustermeier J, Lloveras B
. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11):1048-56.
DOI: 10.1016/S1470-2045(10)70230-8.
View
19.
Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S
. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012; 131(10):2349-59.
DOI: 10.1002/ijc.27485.
View
20.
Lekoane K, Kuupiel D, Mashamba-Thompson T, Ginindza T
. Evidence on the prevalence, incidence, mortality and trends of human papilloma virus-associated cancers in sub-Saharan Africa: systematic scoping review. BMC Cancer. 2019; 19(1):563.
PMC: 6558783.
DOI: 10.1186/s12885-019-5781-3.
View